Skip to main content
. 2018 Oct 23;10:4789–4804. doi: 10.2147/CMAR.S180301

Table 3.

Univariate and multivariate analyses of overall survival in bladder cancer patients

Variable Univariate analyses HR (95% CI) P-value Multivariate analyses HR (95% CI) P-value

Age
≤65 years 1 0.01
>65 years 1.958 (1.175–3.354)
BMI
<24 1 0.277
≥24 0.747 (0.442–1.264)
Gender
Male 1 0.504
Female 0.764 (0.347–1.681)
Smoking history
No 1 <0.001 1 <0.001
Yes 5.046 (2.800–9.093) 4.169 (2.218–7.835)
Hypertension
No 1 0.323
Yes 1.365 (0.736–2.531)
Diabetes mellitus
No 1 0.702
Yes 1.118 (0.632–1.978)
Cardiovascular disease
No 1 0.542
Yes 0.851 (0.507–1.429)
Histology type
Transitional cell carcinoma 0.44
Non-transitional cell carcinoma 1.295 (0.673–2.492)
Grade
1 and 2 1 0.295
3 1.569 (0.675–3.647)
T-stage
NMIBC 1 <0.001 1 0.001
MIBC 6.084 (2.983–12.408) 3.361 (1.601–7.055)
N-stage
Negative 1 0.018
Positive 2.221 (1.147–4.301)
M-stage
Negative 1 0.018 1 0.006
Positive 3.035 (1.208–7.625) 4.006 (1.494–10.742)
ASA grade
1 and 2 1 0.013
3 and 4 2.385 (1.204–4.724)
NLR
≤3.8 1 <0.001
>3.8 2.754 (1.655–4.584)
PLR
≤210.9 1 0.01
>210.9 2.248 (1.212–4.167)
PNI
≤38.5 1 0.002
>38.5 0.380 (0.208–0.692)
CAR
≤0.2 1 <0.001 1 <0.001
>0.2 4.214 (2.500–7.102) 3.063 (1.788–5.249)

Note: P-values <0.05 are shown in bold.

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CAR, C-reactive protein/albumin ratio; MIBC, muscle-invasive bladder cancer; NLR, neutrophil-to-lymphocyte ratio; NMIBC, non-muscle invasive bladder cancer; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index.